Kindred Healthcare Inc. (NYSE:KND) shares fell -1.75% in last trading session and ended the day at $11.23. KND Gross Margin is 94.60% and its has a return on assets of -1.40%. Kindred Healthcare Inc. (NYSE:KND) quarterly performance is -11.38%.
Kindred Healthcare, Inc. (NYSE:KND) announced that Benjamin A. Breier, President and Chief Executive Officer, participate in a “fireside chat” at the Barclays Global Healthcare Conference in Miami, Florida, on Tuesday, March 15, 2016, at 8:00 a.m. Eastern Time.
KMG Chemicals Inc. (NYSE:KMG) ended the last trading day at $23.08. Company weekly volatility is calculated as 3.64% and price to cash ratio as 30.37. KMG Chemicals Inc. (NYSE:KMG) showed a weekly performance of 5.44%.
KMG Chemicals Inc. (NYSE:KMG) announced that its Board of Directors has declared a quarterly cash dividend of $0.03 per common share. The dividend is payable March 18, 2016 to shareholders of record March 11, 2016.
On 17 March, Community Trust Bancorp Inc. (NASDAQ:CTBI) shares advanced 2.02% and was closed at $34.87. CTBI EPS growth in last 5 year was 6.20%. Community Trust Bancorp Inc. (NASDAQ:CTBI) year to date (YTD) performance is 0.65%.
Community Trust Bancorp, Inc., (NASDAQ:CTBI) declared its cash dividend of $0.31 per share, which will be paid on April 1, 2016, to shareholders of record on March 15, 2016.
Albany Molecular Research Inc. (NASDAQ:AMRI) shares fell -0.56% in last trading session and ended the day at $14.19. AMRI Gross Margin is 26.40% and its has a return on assets of -0.40%. Albany Molecular Research Inc. (NASDAQ:AMRI) quarterly performance is -28.37%.
Albany Molecular Research Inc. (NASDAQ:AMRI) announced that it has been recognized as a Life Science Leader CMO Leadership Award recipient in the categories of Expertise (overall, small pharma), Capabilities (small pharma) and Compatibility (small pharma). In 2013, AMRI was awarded a CMO Leadership Award in the Quality category.
Celsion Corp. (NASDAQ:CLSN) caters to the Healthcare space. Its weekly performance is -0.69%. On the last day of trading company shares ended up at $1.43.
Celsion Corporation (NASDAQ:CLSN), announced that its preclinical data for GEN-1 in combination with Avastin® and Doxil® for the treatment of ovarian cancer will be presented at the upcoming AACR Annual Meeting 2016 in New Orleans. The presentation will be held on Monday, April 18, 2016 (1:00 pm to 5:00 pm) and will summarize results from preclinical studies demonstrating significant synergistic anti-cancer effects when GEN-1 is combined with Avastin® and Doxil®, a current Standard of Care (SoC) for platinum resistant ovarian cancer patients. GEN-1 is an IL-12 DNA plasmid vector formulated into a nanoparticle with a non-viral delivery system to cause the sustained local production and secretion of the Interleukin-12 (IL-12) protein loco-regionally to the tumor site.
Leave a Reply